Merck emphasizes its dedication to transparency and accountability, committing to update stakeholders on any material developments

Merck (NYSE: MRK), also known as MSD outside the United States and Canada, disclosed that Dr. Marjorie Green, serving as senior vice president and head of oncology at Merck Research Laboratories, is slated to engage in a fireside chat during the Leerink Partners Global Biopharma Conference 2024. The session is scheduled for Monday, March 11, 2024, at 12:40 p.m. ET. The event invites investors, analysts, media representatives, and the public to join the live audio webcast of the presentation, accessible via a provided web link. Merck recognized as MSD internationally, is dedicated to leveraging cutting-edge science to enhance and preserve lives worldwide.

With a history spanning over 130 years, the company has been instrumental in advancing medicines and vaccines, instilling hope, and contributing to healthcare progress. Positioned as a premier research-intensive biopharmaceutical enterprise globally, Merck is actively engaged in pioneering research aimed at revolutionizing healthcare solutions for disease prevention and treatment in both human and animal domains. The forward-looking statements provided by Merck & Co., Inc., Rahway, N.J., USA, underscore the inherent risks and uncertainties faced by the company. While management's beliefs and expectations guide these statements, actual outcomes may deviate significantly due to inaccurate assumptions or the materialization of risks and uncertainties.